Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois
GlobeNewswire |
With the execution of this agreement, oncologists and pathologists affiliated with this health plan now have the ability to more easily offer
The contract with this
About
About
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.</i>
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the
CONTACT: Investor Relations Contact:Peter Rahmer Trout Group 646-378-2973 Company Contact:Thomas A. Bologna Chairman & Chief Executive Officer 323-224-3900
Source:
Copyright: | 2013 GlobeNewswire, Inc. |
Wordcount: | 742 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News